On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Vifor Pharma (Switzerland)

InstitutionResearch output, impact & collaborations

Vifor Pharma (Switzerland) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Vifor Pharma (Switzerland)?

ScholarIQrecord summary

Vifor Pharma (Switzerland) is a research organisation in Glattbrugg, CH. OpenAlex records 964 works and 58,702 citations for it. 245 researchers list it as their most recent affiliation.

How many works does Vifor Pharma (Switzerland) have?

ScholarIQindexed works

Vifor Pharma (Switzerland) has 964 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Vifor Pharma (Switzerland) →

How many citations does Vifor Pharma (Switzerland) have?

ScholarIQcitation count

Vifor Pharma (Switzerland) has 58,702 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Vifor Pharma (Switzerland) →

How many researchers are at Vifor Pharma (Switzerland)?

ScholarIQresearcher count

Vifor Pharma (Switzerland) has 245 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Vifor Pharma (Switzerland)?

ScholarIQavg h-index

Vifor Pharma (Switzerland) has an average h-index of 15 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Vifor Pharma (Switzerland)?

ScholarIQror

The ROR for Vifor Pharma (Switzerland) is on the source record.

Open the ROR →

What is the OpenAlex record for Vifor Pharma (Switzerland)?

ScholarIQopenalex

The OpenAlex for Vifor Pharma (Switzerland) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Vifor Pharma (Switzerland)?

ScholarIQtop researchers by citations

Antonio Ramírez de Arellano · Diabetes Management and Research

64 works492 citations

What are the most-cited papers on Vifor Pharma (Switzerland)?

ScholarIQmost cited works

The Economic Burden of Insulin-Related Hypoglycemia in Spain

Witesh Parekh, Nicki Hoskins, James Baker‐Knight, Antonio Ramírez de Arellano, Pedro Mezquita Raya

Diabetes Therapy. 201734 CitationsOPEN ACCESS

The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland

Thomas Ward, Tray Brown, Ruth D. Lewis, Melodi Koşaner Kließ, Antonio Ramírez de Arellano, Carol Moreno Quinn

PharmacoEconomics - Open. 202232 CitationsOPEN ACCESS

Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising <scp>AFFIRM‐AHF</scp>

Phil McEwan, Piotr Ponikowski, Jason A. Davis, Giuseppe Rosano, Andrew J.S. Coats, Fabio Dorigotti, Donal O'Sullivan, Antonio Ramírez de Arellano, Ewa A. Jankowska

European Journal of Heart Failure. 202131 CitationsOPEN ACCESS

Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin

Antonio Pérez, Pedro Mezquita Raya, Antonio Ramírez de Arellano, Teresa Briones, Barnaby Hunt, William J. Valentine

Diabetes Therapy. 201530 CitationsOPEN ACCESS

Self-Reported Frequency and Impact of Hypoglycemic Events in Spain

Domingo Orozco‐Beltrán, Pedro Mezquita‐Raya, Antonio Ramírez de Arellano, Manuel Galán

Diabetes Therapy. 201430 CitationsOPEN ACCESS

How much of the research on Vifor Pharma (Switzerland) is open access?

ScholarIQopen access share

100%OPEN ACCESS

Gold

73%

Green

Hybrid

18%

Bronze

Closed